Abstract: This invention relates to a method of detecting or determining the presence of prostate cancer cells in a sample of body fluid from a subject comprising: (i) isolating cells from said sample to provide a cell sample; (ii) contacting said cell sample with a specific binding member capable of binding a prostate antigen; and/or (iii) contacting said cell sample with a specific binding member capable of binding a minichromosome maintenance (MCM) polypeptide(s); and (iv) determining the binding of said specific binding member(s) to the cell sample.

Abstract: In a method for visualizing an object under conditions of low ambient light, the object to be visualized is exposed to incident electromagnetic radiation having a wavelength greater than what can normally be seen by the naked eye. Light reflected from the object is then perceived with an enhanced eye. The enhanced eye contains an up-conversion material optically coupled to the photoreceptors. Up-conversion materials absorb in the infrared and luminesce in the visible. Particles containing such materials are delivered to the eye where they are optically coupled to the retina or photoreceptor cells and nearby tissues. There they provide in-situ up-conversion of infrared frequencies (from about 700 to about 11,000 nm) to the otherwise unaided eye.

Abstract: The present invention relates to the use of at least one nucleic acid comprising or consisting of: (i) CATCGAT-GAAGAACGCWGCRAAHTGCGATAMGTARTGYGAATTGCAGRATTCAGTGARTCATCGAAWYTTTGAACG-CAYMTTGCRC (SEQ ID NO: 1), wherein: R represents A or G Y represents C or T M represents A or C W represents A or T H represents A or C or T (ii) a portion of SEQ ID NO: 1, provided said nucleic acid binds under stringent conditions to a nucleic acid comprising or consisting of the complementary sequence of SEQ ID NO: 1, or (iii) complementary sequences of (i) and (ii); for the detection of nucleic acids from one or more fungi in a sample.

Abstract: The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.

Abstract: The invention relates to the use of methionine synthase inhibitors for the treatment of fungal diseases of crops. The invention further relates to methods for treatment of crops against fungal diseases comprising the application of a methionine synthase inhibitor also methods for the identification of novel fungicidal compounds comprising a step for identification of methionine synthase inhibitors.

Abstract: This invention relates generally to magnetic resonance (MR)-based methods and kits for measuring the viscosity of liquid samples.

Abstract: The present invention relates to a novel mite composition comprising a population of a phytoseiid predatory mite species and a factitious host population, which may be employed for rearing said phytoseiid predatory mite species or for releasing the pyrltoseiid predatory mite species in a crop. According to further aspects the invention relates to a method for rearing a phytoseiid predatory mite species, to the use of the mite composition and to a method for biological pest control in a crop, which employ the mite composition.

Abstract: This invention is related to the treatment of the Multiple Sclerosis (MS). In this invention the disabling thymus gland is suggested as a new method of treatment for MS. This proposed method can be a surgical operation and or drug usage to achieve thymus hypofunction or dysfunction. The idea is targeted on decreasing of the number of T-Cells by reaching a lower level of function of the Thymus Gland. These types of operation leads to stopping (partly or entirely) the maturation process of the blood stem cells to become a T-Cell. Three ways are suggested to achieve the target: 1. Blocking the afferent arteries of thymus gland 2. Thymectomy 3. Using different drugs, which can dysfunction (partly or entirely) the thymus Gland This method can be use as an additional method together with the other well-known methods.

Abstract: Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease.

Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.

Abstract: The invention provides methods and reagents for determination of risk and treatment of a vascular disorder such as abdominal aortic aneurysm (AAA) by detecting presence of gene polymorphisms and/or genetic profiles associated with an elevated or a reduced risk of the disorder. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of an individual which facilitate assessment of risk for developing such diseases.

Abstract: The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence.

Abstract: The present invention relates to an enzyme activity assay using rolling circle amplification for verifying that a sample contains the enzyme activity in question. Thus, the present invention pertains to a method for determining the presence or absence of one or more enzyme activities involved in circularising a non-circular oligonucleotide probe in a biological sample. Furthermore, the present invention concerns liquid compositions comprising one or more oligonucleotide probes. Within the scope of the present invention is also a composition comprising a liquid composition and a tissue sample, and solid support of one or more oligonucleotides of the present invention. Disclosed is also a microfluidic device with one or more compartments for performing rolling circle amplification events, and a method for correlating one or more rolling circle amplification events.

Abstract: Disclosed is a method for the detection of virus variations. Disclosed also is a method for the treatment of virus infection in a subject based on the detection of virus variations. Additionally, a kit is provided for the detection of virus variations.

Abstract: A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The gene may be TWIST1 or a panel of genes such as TWIST1, NID2 and RUNX3 may be screened. The epigenetic change may be methylation. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises at least one primer pair for determining the methylation status of each of NID2, TWIST1 and RUNX3. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises means for detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2.

Abstract: Chemically functionalized fullerenes are useful in various applications as radical scavengers. These chemically functionalized fullerenes offer the advantages of preservation of the high innate radical scavenging efficiency of the fullerene cage and ease of synthesis of fullerene derivatives of desirably altered chemical and physical properties and single isomers. Further, they are based on a common intermediate chemistry and intermediates can be easily functionalized and tailored to various requirements.

Abstract: This invention relates to agricultural compositions, particularly pesticidal compositions which find particular use as a fungicide or herbicide composition. The pesticidal composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the pesticidal composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The pesticidal composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a herbicide and/or harvest aid or desiccant for harvested crops such as potatoes. The addition of an emulsifier further enhances the herbicidal properties of the compositions.

Abstract: A surgical instrument including an injection device and a dosing device. These devices are designed such that a predetermined amount of an adhesive or an adhesive containing filler can be injected into a sealing section of the blood vessel. The blood vessel can then be cut at the filled point and is sealed on both sides.

Abstract: The disclosure describes methods for inducing apoptosis of a selected group of vertebrate cells in vivo by reducing the level of thiamin in the cells. Included are methods for inducing apoptosis of cancer cells. Also described are compounds and compositions for use in methods of thiamin depletion and treating diseases such as cancer, and methods for identifying thiamin-depleting agents and for preparing pharmaceutical compositions.

Abstract: Nucleic acids encoding mouse and human sphingosine kinase type 2 isoforms, methods for detecting agents or drugs which inhibit or promote sphingosine activity and therapeutic agents containing peptides or antibodies to peptides encoded by such nucleic acids.

Abstract: The present invention provides a method for diagnosis end-stage cardiomyopathy includes measuring expression of claudin-5 levels in a patient suspected of suffering from end-stage cardiomyopathy as well as a method for treating end-stage cardiomyopathy includes administering an effective amount of a composition effectively upregulates the claudin-5 or inhibits degradation of claudin-5

Abstract: A C-nitroso moiety derived from a carbon acid with a pKa less than about 25 is bound in a biocompatible polymer as an ester or ether to a pendant hydroxyl group, as an ester to a pendant carboxylic acid or as an amine or amide to a pendant amine moiety. The polymer with c-nitroso moiety bound thereto can be coated on a medical device and/or used for prophylaxis of a patient at risk for restenosis. A c-nitroso moiety bound as amide to polyisobutylene amine substituted styrene copolymer is described in detail.

Abstract: The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

Abstract: Insect refuge strategies are described for the management of insect resistance development. The present invention relates generally to the control of pests that cause damage to crop plants, and in particular to corn plants, by their feeding activities directed to root damage, and more particularly to the control of such plant pests by ensuring, through the seed production process, that sufficient refuge seeds are present in a given set of seeds to reduce the rate of development of resistant pests, thereby eliminating the problems that may arise with regard to refuge compliance. In addition, the treatment of such seed with a chemical or peptide-associated pesticide prior to planting the seed is also disclosed.

Abstract: The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer.

Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention relates to the identification of genetic products expressed in association with tumours and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumours, proteins, polypeptides and peptides which are expressed in association with tumours and to the coding nucleic acids for said proteins, polypeptides and peptides.

Abstract: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.

Abstract: This invention relates to agricultural compositions that find particular use as a fungicide composition. The fungicide composition can include one or more fatty acids and one or more organic acids different from the fatty acid. The organic acid can but need not exhibit any fungicidal activity; however, when combined with a fatty acid, the organic acid functions as a potent synergist for the fatty acid as a fungicide. Additionally, the fungicide composition can include other components such as emulsifiers, adjuvants, surfactants and diluents. The fungicide composition significantly reduces or prevents the fungal infection of cash crops including vegetables, fruits, berries, seeds, grains and at higher application rates, can also be used as a harvest aid or desiccant for harvested crops such as potatoes.

Abstract: In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus.

Abstract: Disclosed herein are imidazo[1,5-f][1,2,4]triazine compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). The imidazo[1,5-f][1,2,4]triazine compounds described are irreversible inhibitors of Btk. Methods for the preparation of the imidazo[1,5-f][1,2,4]triazine compounds are disclosed. Also disclosed are pharmaceutical compositions that include the imidazo[1,5-f][1,2,4]triazine compounds. Methods of using the imidazo[1,5-f][1,2,4]triazine Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions; cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.

Abstract: A system and methods are described for improving the management of ischemic cardiac tissue during acute coronary syndromes. The system combines a catheter-based sub-system which allows for simultaneous balloon dilation of a coronary artery and infusion of a carefully controlled perfusate during percutaneous coronary intervention. The system allows for modulation of levels of oxygen at the time of percutaneous intervention. In addition, catheters and systems are provided for administration of fluids with modified oxygen content during an intervention that incorporate upstream flow control members to compartmentalize the perfusion of the target coronary artery and the remainder of the heart.

Abstract: The present invention concerns the use of methods for evaluating bucindolol treatment for a patient, particularly one with heart failure. It concerns methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient is homozygous for the Arg 389 polymorphism in the ?1-adrenergic receptor (AR).

Abstract: Provided are methods and apparatus for high throughput testing of biological samples that may or may not comprise microorganisms. The methods include the use of a diagnostic multiplexing panel (DMP) specifically designed for the simultaneous identification of a plurality of potential microorganisms that may be present in the biological sample via a primer extension reaction directed a highly conserved nucleic acid sequences in the microorganisms under test. The biological sample is typically immobilised on a solid substrate at a first location before being transferred to a second location for analysis using the DMP. The methods and apparatus of the invention are particularly suited to diagnosis of the presence of infectious pathogens in the biological sample, for example for diagnosis of sexually transmitted infection.

Abstract: Ornithine ?-aminotransferase (OAT) facilitates microtubule assembly in addition to its aminotransferase activity in mitochondria. An N-terminal proteolysis of the first 17 amino acids of OAT block its transport to the mitochondria. The resultant truncated protein (OATC) forms specific complexes with mitotic spindle promoting proteins such as Eg5 and takes on a Ran-dependent spindle-assembly activity. Methods and compositions for inhibiting mitotic spindle assembly in a cell by specifically inhibiting OAT, and methods for screening for inhibitors of (1) the spindle-assembly function of OAT, (2) the protease that N-truncates OAT, (3) the OAT/RanGTP association and (4) the OAT/Eg5 association are disclosed.

Abstract: A pesticide or herbicide formulation comprising an effective amount of a pesticide or herbicide in a carrier or solvent fluid, wherein the carrier or solvent fluid comprises a Fischer-Tropsch hydrocarbon produced via Fischer-Tropsch conversion of synthesis gas. A method of producing a pesticide or herbicide formulation by combining an amount of an herbicide or pesticide and a biodegradable solvent to form a pesticide or herbicide solution. A method of producing a pesticide or herbicide formulation by converting synthesis gas into Fischer-Tropsch products in the presence of a Fischer-Tropsch catalyst and combining at least one Fischer-Tropsch product with a pesticide or herbicide to create the formulation.

Abstract: Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: Compositions containing a carrier and microbubles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope formed of at least one base lipid and at least one emulsifying agent. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs.

Abstract: Methods and agents are disclosed for modulating the interaction of ?-catenin or ?-catenin with CBP or p300. Agents that increase the binding of CBP to ?-catenin are associated with enhancing the ?-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells.

Abstract: A skin treatment system includes a flexible panel having an outer surface and an inner surface. The flexible panel may be configured to surround at least a portion of a user's appendage. The skin treatment system may also include at least one skin treatment insert having an inner surface and an outer surface. The flexible panel may be further configured to releasably engage the skin treatment insert. The skin treatment insert may be configured to receive a topical skin treatment. The inner surface of the skin treatment insert may be configured to apply the topical skin treatment to at least a portion of a surface of the user's appendage.

Abstract: A preharvest coating for fruits, vegetables and other plants includes a primary ingredient for protecting the fruit, vegetable or plant from physical harm or damage during growing and harvesting and/or for enhancing the appearance of the fruit, vegetable or plant. In addition, the coating includes a nutraceutical component that may provide health beneficial effects to human consumers of the fruit, vegetable or plant. Such nutraceutical components can include phytonutrients such as flavonoids, stilbenes or other phytochemicals. Preferably, the nutraceutical component is included in an otherwise conventional coating and is applied by means of preharvest thermofogging of the fruit, vegetable or plant.

Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders and cancer.

Abstract: The present invention provides a medicinal composition comprising (1) a pharmacologically active substance, (2) a drug absorbefacient and (3) a taurine compound or a polyamine. A taurine compound has an effect of suppressing or preventing damage of the intestinal mucous membrane, and therefore adding the taurine compound to a medicinal composition containing a pharmacologically active substance and a drug absorbefacient makes it possible to suppress or prevent damage of the intestinal mucosa. A polyamine improves the absorbability of pharmacologically active substances, and therefore adding the polyamine to a medicinal composition containing a pharmacologically active substance and a drug absorbefacient makes it possible to decrease the dose of the drug absorbefacient, thereby suppressing or preventing damage of the intestinal mucosa.

Abstract: The present invention relates to a skin care composition comprising at least two oil phases dispersed in a continuous aqueous phase comprising a thickening agent, wherein a first oil phase of the oil phases has different composition from the other oil phase, and wherein the composition contains an emulsifier no more than 1.0%. The present invention also relates to a method of preparing a skin care composition comprising dispersing a first oil phase in a continuous aqueous phase comprising a thickening agent; and dispersing a second oil phase in the continuous aqueous phase; wherein composition of said first oil phase differs from composition of said second oil phase, and wherein the composition contains an emulsifier no more than 1.0%.

Abstract: The present invention provides a novel dry powder inhalation system suitable for transpulmonary administration. The dry powder inhalation system of the invention characterized by using a combination of: (1) a vessel housing a freeze-dried composition that contains a single dose of an active ingredient, and has: (i) a non-powder cake-like form, (ii) a disintegration index of 0.015 or more, and (iii) a property of becoming fine particles having a mean particle diameter of 10 microns or less or a fine particle fraction of 10% or more upon receipt of an air impact having an air speed of at least 1 m/sec and an air flow rate of at least 17 ml/sec; and (2) a device comprising means capable of applying said air impact to the freeze-dried composition in said vessel, and means for discharging the powder-form freeze-dried composition that has been made into fine particles.

Abstract: The present invention includes methods and devices for non-invasively delivering an active agent to the eye of a subject. In one aspect, for example, a device for delivering an active agent to an eye of a subject may include an ocular lens-shaped housing configured to contact a surface of the eye, and a reservoir coupled to the housing and configured to deliver an active agent to the eye, wherein the reservoir is located entirely within a 180 degree section of the housing. In another aspect, the reservoir is located entirely within a 150 degree section of the housing.

Abstract: Reduction of platelet counts to below 150 thousand per cubic millimeter by pharmacologic, mechanical, combined mechanical and pharmacological, or other means for the purpose of reducing the incidence and severity of vascular disease in at risk populations, for the stabilization and reversal of said disease in patients already known to suffer from such disease, as well as for the purpose of preventing and/or reducing the incidence and severity of sequelae related to such disease, whether preclinical, subclinical or overtly manifested, or whether it is presently understood to be related to said vascular disease or not.

Abstract: The present invention is a cell-based method of identifying a set of signal transduction proteins having an intracellular localization pattern responsive to toxic compounds. The method requires identifying and screening an initial set of signal transduction proteins against a set of toxic compounds, and determining changes in intracellular localization pattern of each of the proteins. Proteins whose changes in intracellular localization pattern are redundant are discarded from the initial set, and new proteins are added to provide a new set of proteins. I repeat the method steps with new sets of proteins until the set of proteins provides me at least 5 principal components with respect to the range of compounds marketed as small organic molecules.